Setidegrasib is the first drug in its class to degrade the KRAS protein, a mutation often found in cancer. A phase I study showed promising efficacy of this drug in patients with advanced pancreatic ductal adenocarcinoma (PDAC) with the KRAS G12D mutation. The drug has also been tested in patients with non-small cell lung cancer (NSCLC) with similar positive results. Patients in the study had previously been treated with other therapies. Setidegrasib represents a new approach to the treatment of these aggressive types of cancer, which usually have a poor prognosis. This drug could open up new treatment options for patients with KRAS mutations that have been difficult to treat until now.